{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"59"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"137"}],"title":"No"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"385"},{"groupId":"OG001","value":"196"}],"units":"Participants"}],"description":"The number of hospitalizations (yes/no) (admitted as in-patient) was collected as part of the hospital admission for health economic evaluations.","groups":[{"description":"Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used","id":"OG000","title":"Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)"},{"description":"Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator","id":"OG001","title":"Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"PFS Full Analysis Set (PFS-FAS)","reportingStatus":"POSTED","timeFrame":"From date of randomization till 30 days safety fup, assessed up to approximately 32 months (Primary Analysis cut-off date = 27-Jan-2021)","title":"Number of Participants Hospitalized as In-patient","type":"SECONDARY","unitOfMeasure":"Participants"}